Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study, to be conducted at Rigshospitalet in Copenhagen, Denmark, will enroll up to 39 patients and prospectively select participants based on PTGR1 overexpression and DNA-damage-repair deficiency.
The trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies, addressing a significant unmet need in bladder cancer treatment. Lantern Pharma is advancing its AI-driven precision oncology strategy through its proprietary RADR® platform, which uses machine learning to identify biomarkers and optimize patient selection for clinical trials.
This development is important because it represents a step toward personalized medicine in oncology, where treatments are tailored to the genetic profile of a patient's tumor. If successful, LP-184 could provide a new therapeutic option for bladder cancer patients who have exhausted current treatments. Additionally, the trial's biomarker-guided design may improve the likelihood of clinical benefit and reduce the risk of exposing patients to ineffective therapies.
Lantern Pharma's clinical pipeline also includes LP-284, targeting hematologic and solid tumors, and LP-300, being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
The company's RADR® platform and its multi-agentic AI co-scientist platform, withZeta.ai, are key components of its strategy to transform cancer therapy development. withZeta.ai is commercially available as a subscription-based research platform, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The EMA clearance for this trial underscores the potential of AI-driven approaches in drug development and may pave the way for more efficient and effective oncology trials in the future.
